Nephrology Center of Excellence

Supporting patients living with a rare nephrology condition

Orsini’s Nephrology Center of Excellence launched in 2020 with our first program for primary hyperoxaluria type 1. Today we support multiple nephrology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Nephrology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Nephrology Conditions Supported

Explore the rare nephrology conditions and therapies Orsini supports below.

About Fabry disease

Fabry disease belongs to a group of diseases known as lysosomal storage disorders. It is a rare inherited disorder of lipid (fat) metabolism which results from the deficient activity of the enzyme, alpha-galactosidase A (a-Gal A). This leads to a buildup of a particular type of fat in the body’s cells, called globotriaosylceramide or GL-3, that affects many parts of the body. Signs and symptoms may include episodes of pain, particularly in the hands and feet, clusters of small, dark red spots on the skin, a decreased ability to sweat, cloudiness of the front part of the eye and hearing loss. Complications such as progressive kidney damage, heart attack, and stroke can be life-threatening.

Fabry Disease Therapies Supported

Full Name	Elfabrio® (pegunigalsidase alfa-iwxj)
Drug	Elfabrio
Manufacturer	Chiesi
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of adults with confirmed Fabry disease
Disease	Fabry disease
Therapeutic Area	Neurology, Nephrology, Genetics
Enrollment Form Link	Enrollment Form
Phone Number	833-656-1056
Fax Number	636-355-3610
Product Website	hcp.elfabrio.com

Full Name	Fabrazyme® (agalsidase beta)
Drug	Fabrazyme
Manufacturer	Sanofi Genzyme
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Disease	Fabry disease
Therapeutic Area	Neurology, Nephrology, Genetics
Enrollment Form Link	Enrollment Form
Phone Number	800-240-9572
Fax Number	877-220-7581
Product Website	hcp.fabrazyme.com

About Homozygous Cystinuria

Homozygous cystinuria is a rare genetic disorder characterized by the presence of two identical mutations in the genes responsible for cystine transport in the kidneys. This results in impaired reabsorption of cystine, leading to its excessive accumulation in the urine. Cystine forms crystals that can combine to create kidney stones, causing recurrent and often painful episodes of nephrolithiasis. Individuals with homozygous cystinuria face an increased risk of kidney damage and related complications.

Homozygous Cystinuria Therapies Supported

Full Name	tiopronin
Drug	Tiopronin
Manufacturer	Generic
Route of Administration	Oral
Site of Care	Home
Approved Indication	In combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone
Disease	Homozygous Cystinuria
Therapeutic Area	Nephrology
Enrollment Form Link	Tiopronin Enrollment Form
Phone Number	800-764-0147
Fax Number	877-848-6579
Product Website

About Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that usually is eliminated by the kidneys and excreted in the urine. The excess production of oxalate results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis, progression to kidney failure, and systemic organ dysfunction. It is estimated that PH1 affects one to three individuals per million in the United States and Europe.

PH1 Therapies Supported

Full Name	Oxlumo® (lumasiran)
Drug	Oxlumo
Manufacturer	Alnylam Pharmaceuticals
Route of Administration	Subcutaneous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Disease	Primary Hyperoxaluria Type 1 (PH1)
Therapeutic Area	Nephrology
Enrollment Form Link	Oxlumo Enrollment Form
Phone Number	800-460-5217
Fax Number	877-276-8563
Product Website	oxlumo.com

About Urea Cycle Disorders (UCDs)

Urea cycle disorders are a group of rare, genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments if ammonia levels are not controlled. Any increase in ammonia over time is serious. Therefore, it is important to adhere to any dietary protein restrictions and have alternative medication options to help control ammonia levels.

UCD Therapies Supported

Full Name	OLPRUVA^® (sodium phenylbutyrate)
Drug	Olpruva
Manufacturer	Zevra Therapeutics, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m2 or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)
Disease	Urea Cycle Disorders (UCDs)
Therapeutic Area	Nephrology
Enrollment Form Link	Enrollment Form
Phone Number	800-837-8905
Fax Number	877-369-3806
Product Website	olpruvahcp.com